Pharma Bio Services (PBSV)
OTHER OTC:PBSV
Want to see PBSV full AI Analyst Report?
PBSV Stock Chart & Stats
$0.54
-$0.14(-25.27%)
At close: 4:00 PM EST
$0.54
-$0.14(-25.27%)
Day’s Range― - ―
52-Week Range$0.43 - $1.36
Previous CloseN/A
Volume2.02K
Average Volume (3M)2.53K
Market Cap
$12.94M
Enterprise Value-$5.75B
Total Cash (Recent Filing)$10.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.09
Next Earnings
Jun 17, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding22,901,691
10 Day Avg. Volume1,930
30 Day Avg. Volume2,531
Financial Highlights & Ratios
PEG Ratio1.42
Price to Book (P/B)1.04
Price to Sales (P/S)1.38
P/FCF Ratio-55.94
Enterprise Value/Market Cap-444.42
Enterprise Value/Revenue-651.64
Enterprise Value/Gross Profit-2.01K
Enterprise Value/Ebitda18.39K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.09
Revenue Forecast (FY)$11.50M
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Balance SheetA near-zero debt-to-equity level materially reduces financial risk and preserves strategic optionality. This balance sheet strength supports multi-month resilience, capacity to fund initiatives or absorb shocks without urgent refinancing, and underpins long-term survivability.
Recent Strong Revenue Growth (TTM)A 116.4% TTM revenue surge signals meaningful demand expansion or successful commercial execution. If sustained, this scale expansion can improve unit economics, enhance market position and enable investments in operations and sales that support durable growth over the coming months.
Solid Gross Margin (~29.3%)A ~29.3% gross margin provides a durable cushion to absorb input cost swings and supports the path to positive operating leverage. With disciplined SG&A and improved operating efficiency, this margin base could translate into sustainable profitability over a multi-month horizon.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow erodes internal funding and forces reliance on external financing or equity raises. Over 2–6 months this constrains capital allocation, limits reinvestment, and increases liquidity and execution risk for strategic initiatives.
Negative Operating Profitability (EBIT/EBITDA)Negative EBIT and EBITDA indicate the company is not yet converting revenue into operating profits. This undermines returns on capital and makes funding dividends or growth internally unsustainable without a credible path to margin improvement over the medium term.
Earnings Volatility And Uneven ResultsSwitching from profits to losses across recent years reflects execution or demand variability, complicating forecasting and strategic planning. This volatility raises execution risk, weakens stakeholder confidence, and hampers long-term investment decisions.
Pharma Bio Services News
PBSV FAQ
What was Pharma Bio Services’s price range in the past 12 months?
Pharma Bio Services lowest stock price was $0.43 and its highest was $1.36 in the past 12 months.
What is Pharma Bio Services’s market cap?
Pharma Bio Services’s market cap is $12.94M.
When is Pharma Bio Services’s upcoming earnings report date?
Pharma Bio Services’s upcoming earnings report date is Jun 17, 2026 which is in 12 days.
How were Pharma Bio Services’s earnings last quarter?
Pharma Bio Services released its earnings results on Mar 17, 2026. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.02 by -$0.02.
Is Pharma Bio Services overvalued?
According to Wall Street analysts Pharma Bio Services’s price is currently Overvalued.
Does Pharma Bio Services pay dividends?
Pharma Bio Services pays a Notavailable dividend of $0.075 which represents an annual dividend yield of N/A. See more information on Pharma Bio Services dividends here
What is Pharma Bio Services’s EPS estimate?
Pharma Bio Services’s EPS estimate is 0.03.
How many shares outstanding does Pharma Bio Services have?
Pharma Bio Services has 22,901,691 shares outstanding.
What happened to Pharma Bio Services’s price movement after its last earnings report?
Pharma Bio Services reported an EPS of $0 in its last earnings report, missing expectations of $0.02. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Pharma Bio Services?
Currently, no hedge funds are holding shares in PBSV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharma Bio Services
Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm. The company provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products companies in Puerto Rico, the United States, Europe, and Brazil. Its technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.
Technical Analysis
Zhongchao
―
Healthcare Triangle
―
VSee Health
―
Aclarion, Inc.
―
BullFrog AI Holdings, Inc.
―
Ownership Overview
10.80%
Insiders
― Other Institutional Investors
89.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---